Patricia Gaule, PhD, BSc
Associate Research Scientist
Research & Publications
Biography
Coauthors
Selected Publications
- BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.Madden SF, Clarke C, Gaule P, Aherne ST, O'Donovan N, Clynes M, Crown J, Gallagher WM. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Research : BCR 2013, 15: R52 PubMed ID: 23820017, PMCID: PMC3978487, DOI: 10.1186/bcr3444.
- cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Gaule PB, Crown J, O'Donovan N, Duffy MJ. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? Expert Opinion On Therapeutic Targets 2014, 18: 999-1009 PubMed ID: 25084805, DOI: 10.1517/14728222.2014.938050.
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology 2017, 3: 256-259 PubMed ID: 27541827, PMCID: PMC5491359, DOI: 10.1001/jamaoncol.2016.3015.
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 370-378 PubMed ID: 27440266, PMCID: PMC6350535, DOI: 10.1158/1078-0432.CCR-16-0150.
- Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL. Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. Journal For Immunotherapy Of Cancer 2017, 5: 25 PubMed ID: 28331615, PMCID: PMC5359951, DOI: 10.1186/s40425-017-0229-2.
- B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 5202-5209 PubMed ID: 28539467, PMCID: PMC5581684, DOI: 10.1158/1078-0432.CCR-16-3107.